Greenyn Biotechnology Co., Ltd. (6846) Stock Statistics & Valuation Metrics

Greenyn Biotechnology Co., Ltd. has a market cap or net worth of TWD 1.33B. The enterprise value is TWD 2.33B.

Market Cap

TWD 1.33B

Enterprise Value

TWD 2.33B

Greenyn Biotechnology Co., Ltd. has 27,066,038 shares outstanding. The number of shares has decreased by -2.65% in one year.

Shares Outstanding

27,066,038

Owned by Insiders

―

Owned by Institutions

―

Greenyn Biotechnology Co., Ltd.’s return on equity (ROE) is 0.15 and return on invested capital (ROIC) is 7.78%.

Return on Equity (ROE)

0.15

Return on Assets (ROA)

0.07

Return on Invested Capital (ROIC)

7.78%

Return on Capital Employed (ROCE)

0.10

Revenue Per Employee

6.40M

Profits Per Employee

1.02M

Employee Count

143

Asset Turnover

0.43

Inventory Turnover

2.68

The current PE Ratio of Greenyn Biotechnology Co., Ltd. is 10.32. Greenyn Biotechnology Co., Ltd.’s PEG ratio is -0.86.

PE Ratio

10.32

PS Ratio

1.51

PB Ratio

1.43

Price to FCF

-3.94

Price to Operating Cash Flow

10.10

PEG Ratio

-0.86

In the last 12 months, Greenyn Biotechnology Co., Ltd. had revenue of 915.32M and earned 145.52M in profits. Earnings per share was 5.39.

Revenue

915.32M

Gross Profit

440.04M

Operating Income

188.63M

Pretax Income

184.96M

Net Income

145.52M

EBITDA

224.08M

Earnings Per Share (EPS)

5.39

In the last 12 months, operating cash flow was 130.03M and capital expenditures -463.13M, giving a free cash flow of -333.10M billion.

Operating Cash Flow

130.03M

Free Cash Flow

-333.10M

Free Cash Flow per Share

-12.31

Greenyn Biotechnology Co., Ltd. pays an annual dividend of ―, resulting in a dividend yield of 8.05%

Dividend Per Share

―

Dividend Yield

8.05%

Payout Ratio

N/A

Free Cash Flow Yield

-24.37%

Earnings Yield

9.31%

Beta

0.36

52-Week Price Change

-32.69%

50-Day Moving Average

57.77

200-Day Moving Average

63.03

Relative Strength Index (RSI)

17.15

Average Volume (3m)

12.22K

Greenyn Biotechnology Co., Ltd. upcoming earnings date is Nov 12, 2026, TBA (Not Confirmed).

Last Earnings Date

May 12, 2026

Next Earnings Date

Nov 12, 2026

Ex-Dividend Date

―

Greenyn Biotechnology Co., Ltd. as a current ratio of 6.84, with Debt / Equity ratio of 93.56%

Current Ratio

6.84

Quick Ratio

6.02

Debt to Market Cap

0.43

Net Debt to EBITDA

0.55

Interest Coverage Ratio

15.76

In the past 12 months, Greenyn Biotechnology Co., Ltd. has paid 39.44M in taxes.

Income Tax

39.44M

Effective Tax Rate

0.21

Greenyn Biotechnology Co., Ltd. EV to EBITDA ratio is 9.28, with an EV/FCF ratio of -5.70.

EV to Sales

2.19

EV to EBITDA

9.28

EV to Free Cash Flow

-5.70

EV to Operating Cash Flow

14.61

Greenyn Biotechnology Co., Ltd. has TWD 1.18B in cash and marketable securities with TWD 1.22B in debt, giving a net cash position of -TWD 33.14M billion.

Cash & Marketable Securities

TWD 1.18B

Total Debt

TWD 1.22B

Net Cash

-TWD 33.14M

Net Cash Per Share

-TWD 1.22

Tangible Book Value Per Share

TWD 33.81

Gross margin is 46.72%, with operating margin of 18.19%, and net profit margin of 14.67%.

Gross Margin

46.72%

Operating Margin

18.19%

Pretax Margin

18.69%

Net Profit Margin

14.67%

EBITDA Margin

23.60%

EBIT Margin

18.97%

The average price target for Greenyn Biotechnology Co., Ltd. is ―, which is 11.43% higher than the current price. The consensus rating is ―

Price Target

―

Price Target Upside

―

Analyst Consensus

―

Analyst Count

―

Revenue Growth Forecast

-3.33%

EPS Growth Forecast

-11.57%